New drugs in clinical development in the United States.
Over the past few years, a number of new antineoplastic agents have reached the clinical arena. These agents have demonstrated activity in a wide variety of preclinical tumor models and many have been found to have novel mechanisms of action. Some of these new agents are now in Phase I and Phase II trials demonstrating antitumor activity and unique toxicity profiles. In this article, the authors review some of the new agents in clinical development in the United States.
Eckardt
J R
JR
University of Texas Health Science Center, San Antonio.
Von Hoff
D D
DD
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D014481:United States
D000970:Antineoplastic Agents